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Background:  Temporary  vena cava  ﬁlters  have  been  used  for protection  from  potentially  fatal  pulmonary
embolism.  However,  recent  reports  suggested  that  they  may  be associated  with  serious  adverse  com-
plications  including  ﬁlter-related  thrombosis.  The  purpose  of  this  study  was  to  examine  the clinical
complications  of temporary  vena  cava  ﬁlter  placement.
Methods:  We  enrolled  40  consecutive  patients  from  January  2006  to December  2010 who  underwent
percutaneous  temporary  vena  cava  ﬁlter  insertion  in  Saitama  Medical  Center,  Jichi  Medical  University.enous thromboembolism
emporary infra vena cava ﬁlter
eep vein thrombosis
ulmonary embolism
Results:  Major  ﬁlter  complications  related  to temporary  vena  cava  ﬁlters  were  ﬁlter  thrombosis  in  4
patients (10.2%),  ﬁlter  dislocation  in 4 (10.2%),  and catheter-related  infection  in  3  (7.7%).  Massive  pul-
monary  embolism  and  cardiogenic  shock  was  observed  in  one  case  (2.5%)  at the  time  of retraction.
Conclusion:  Temporary  ﬁlter  placement  was  associated  with  a high  incidence  of  device-related  com-
plications.  The  beneﬁt  of  temporary  ﬁlter  placement  should  be  judiciously  weighed  against  the  risk  of
complications.
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Anticoagulation therapy has been the standard treatment for
eep venous thrombosis (DVT) and pulmonary embolism (PE)
1–5]. Permanent inferior vena cava (IVC) ﬁlters have been in clin-
cal use since 1967 and gained acceptance for the prevention of PE
rising from DVT in the lower extremities. A randomized controlled
tudy in Europe indicated that a permanent IVC ﬁlter decreased the
ong-term incidence of recurrent symptomatic PE [6].  However,
tudies showed that permanent IVC ﬁlters were associated with
ncreased risk of complications such as IVC thrombosis, recurrent
enous thromboembolism, thrombophelebitis, and venous stasis
isease [1,7–10].
Temporary IVC ﬁlters, connected outside through a tethering
atheter, are designed to avoid the long-term adverse outcomes of
ermanent ﬁlters and are used in Europe and Japan. The Food and
rug Administration has not yet approved them for use in the USA
11]. Retrieval of temporary IVC ﬁlter needs only extraction without
ny other supportive devices, while additional devices (e.g. hooks
r catheters) are required for the retrieval of permanent IVC ﬁlters
retrieval type). The indications for a temporary IVC ﬁlter, however,
re not well established due to lack of prospective, randomized
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controlled studies. The use of IVC ﬁlters is still controversial [12,13].
In this study, we  reviewed the clinical experience of temporary
IVC ﬁlter insertion at our institution, especially with regard to its
complications.
Methods
Between January 2006 and December 2010, we enrolled 40
consecutive patients (21 men  and 19 women) who underwent per-
cutaneous insertion of a temporary IVC ﬁlter. The procedures were
performed in the Department of Cardiovascular Medicine, Saitama
Medical Center, Jichi Medical University.
The use of temporary IVC ﬁlter insertion was determined
according to Japanese guideline of diagnosis, therapy, and preven-
tion of PE and venous thromboembolism (VTE) [14]. The guideline
states that the indication for temporary IVC ﬁlter is to prevent PE
within several weeks in the indication of permanent IVC ﬁlter. The
indications for permanent IVC ﬁlter in the guideline were as fol-
lows: (1) VTE with contraindication to anti-coagulation therapy
(Class I); (2) VTE with complication or side effect of anti-coagulation
therapy (Class I); (3) VTE in pelvic vein or IVC (class II a); (4)
proximal large ﬂoating thrombus (Class II a); (5) PTE with the indi-
cation of thrombolysis or thromboendoathelectomy (Class II a); (6)
VTE with poor residual cardiopulmonary function (Class II a); or
(7) high-risk cases of anti-coagulation (motor ataxia) (Class II a),
chronic thromboembolytic pulmonary hypertension (CTEPH) with
the indication of thromboendoathelectomy (Class II a).
vier Ltd. All rights reserved.
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Table 1
Background of insertion of temporary vena cava ﬁlters.
Mean, SD or number (%)
Age, year 57.2 ± 14.7
Male sex, n (%) 21 (52.5%)
Basic condition
Malignancy 16 (40.0%)
Gynecologic 6 (15.0%)
Genitourinary 4 (10.0%)
Gastrointestinal 4 (10.0%)
Lung 2 (5.0%)
Pelvic mass (excluding malignancy) 3 (7.5%)
Orthopedic disease 2 (5.0%)
Central nervous system disorder 2 (5.0%)
Multiple trauma 1 (2.5%)
Pregnancy 1 (2.5%)
Fulminant myocarditis 2 (5.0%)
Aortic aneurysm 2 (5.0%)
Aortic dissection 2 (5.0%)
Predisposing factors
Immobilization 13 (32.5%)
Postoperative status 5 (12.5%)
Obesity 6 (15.0%)
Estrogen-receptor therapy 1 (2.5%)
Thrombophilia 2 (5.0%)
Protein C deﬁciency 1 (2.5%)
Protein S deﬁciency 1 (2.5%)
Duration of admission, days 23.2 ± 11.0
Duration of ﬁlter placement, days 10.5 ± 5.0
D-dimer, mg/dl 27.0 ± 39.8
Location of DVT (highest level)
Popliteal 13 (32.5%)
Femoral 9 (22.5%)
Iliac 13 (32.5%)
Inferior vena cava 5 (12.5%)
Additional treatments
Warfarin 39 (97.5%)
Urokinase 35 (87.5%)
Tissue plasminogen activator 1 (2.5%)
Catheter Intervention for PE 1 (2.5%)
Unfractionated heparin 1 (2.5%)
DVT, deep vein thrombosis; PE, pulmonary embolism.
Table 2
Major ﬁlter complications of temporary vena cava ﬁlters.
Total number of ﬁlter insertions 40
Major ﬁlter complications, total 14 (35.8%)
IVC thrombosis 4 (10.2%)
Filter dislocation 4 (10.2%)
Catheter-related infection 3 (7.7%)
Massive PE at retraction 1 (2.6%)
Venous perforation 1 (2.6%)Fig. 1. Tip of temporary vena cava ﬁlter.
We  used a temporary ﬁlter system (Neuhause Protect®, Toray
edical, Tokyo, Japan) in all the patients (Fig. 1). All ﬁlters were
nserted percutaneously under ﬂuoroscopic guidance through the
ugular vein. Cavography was performed to ensure that upper
xtremity of the ﬁlter was located in the IVC, immediately below
he renal vein. According to the manual of this device, saline was
ripped intravenously at the speed of 40 ml/h through a micro-
atheter. The position of the ﬁlter was conﬁrmed by X ray every day.
nticoagulation therapy was administered during ﬁlter placement
n all patients if not contraindicated. We  administrated intravenous
ose-adjusted heparin to maintain the activated partial thrombo-
lasmin time at 1.5–2 times of the control value.
We used multislice computed tomography (MDCT) in all the
ases to examine the entrapment of thrombi in the ﬁlter 7–14 days
fter insertion and re-examined this by vena cavography before
etraction. We  examined the complications resulting from tempo-
ary IVC ﬁlter placement during admission.
esults
atient characteristics
The patient characteristics are listed in Table 1. The mean length
f ﬁlter placement was 10.5 ± 5.0 days. The indications for retriev-
ng or exchanging the vena cava ﬁlter were (1) anticoagulation
herapy reached adequate level (prothrombin time-international
ormalized ratio 1.6–2.6 or 2.0–3.0) [15,16],  (2) disappearance
f DVT by MDCT, and (3) complication of ﬁlter itself. DVT was
valuated by duplex scanning or computed tomography (CT), and
ulmonary embolism was evaluated by CT and pulmonary ventila-
ion/perfusion scan. At the time of ﬁlter implantation, all patients
100%) had proven DVT. DVT was present up to the IVC in 5 patients,
he iliac vein in 13, the femoral vein in 9, and the popliteal vein in
3. PE was detected in 25 (65.5%) of these patients before ﬁlter
nsertion. Temporary IVC ﬁlter was inserted in 13 (32.5%) patients,
ue to venous thrombus in popliteal thrombus.Pneumothorax 1 (2.6%)
IVC, inferior vena cava; PE, pulmonary embolism.
Complications
Representative cases of ﬁlter-related massive venous thrombus
and dislocation to hepatic vein are shown in Figs. 2 and 3.
The complications of temporary vena cava ﬁlter are listed in
Table 2. There was  1 case of PE at the time of retraction. Four-
teen patients (35.0%) experienced major and minor complication
problems during ﬁlter protection and retraction.
Discussion
The present study showed that temporary IVC ﬁlter place-
ment was  associated with a high complication rate, including IVC
thrombus, ﬁlter dislocation, catheter-related infection, venous per-
foration, pneumothorax, and massive PE at the time of extraction.
PE is a fatal complication of DVT. Permanent IVC ﬁlters have
been used based on the speculation that they would be effective to
308 H. Wada et al. / Journal of Cardiology 60 (2012) 306–309
Fig. 2. Filter-related massive venous thrombus in right atrium and inferior vena cava. The thrombus appeared 4 days after ﬁlter insertion. The level of D-dimer was  22.9 g/ml
on  admission. The level of prothrombin time-international normalized ratio was kept controlled to 1.8, and activated partial thromboplastin time to 1.6 times of the control
value  during ﬁlter placement. This case fell into cardiogenic shock with massive pulmonary embolism at the time of retrieval of the ﬁlter and required percutaneous
cardiopulmonary support.
Fig. 3. Dislocation to hepatic vein. Filter-related thrombus appeared from the level of infra-renal vein (the place where temporary ﬁlter was placed on admission) to the
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wop  of ﬁlter 13 days after insertion (left). Next day the ﬁlter dislocated to hepatic v
ime-international normalized ratio was kept controlled to 2.0, and activated partia
ble  to retrieve the ﬁlter in the catheter laboratory without any symptomatic pulm
revent PE in case of DVT of lower limbs [17–22].  However, many
andomized trials suggested that the beneﬁt of permanent IVC
lters to prevent PE was offset by the demerit of ﬁlter-derived com-
lications in the long term. The indication for a permanent IVC ﬁlter
as limited to the patients contraindicated for anti-coagulation
23]. It may  be safe to state that there is a paucity of data about
he comparison with effectiveness versus safety of temporary IVC
lter placement [11].
The only randomized, controlled trial regarding permanent IVC
lters has been reported by Decousus et al. [6].  This report indicated
hat in high-risk patients with proximal DVT, the initial beneﬁcial
ffect of an IVC ﬁlter together with anticoagulants for the preven-
ion of PE was counter balanced by an excess of recurrent DVT,
ithout any difference in mortality [7].  A high incidence of com-
lications related to temporary ﬁlters suggests that this device has
imited indications.
The chief reasons why we used Neuhaus protect as ﬁrst choice of
emporary IVC ﬁlter were its retrievability and less damage to IVC
all without penetration of metal tip. Previous reports suggestedight). The level of D-dimer was 5.1 g/ml on admission. The level of prothrombin
mboplastin time to 2.6 times of the control value during ﬁlter placement. We were
 embolism or injury to superior vena cava.
that retrieval Gyunter Tulip Filter (GTF) for temporary use showed
clinical usefulness to prevent PE in 66 cases, however, in 6 cases
(9.1%) they failed to retrieve the ﬁlters. Our report showed that
Neuhaus protect was  able to be retrieved completely in all cases;
however there was a high rate of complications (35%), such as ﬁlter-
related thrombosis and dislocation.
In the Japanese guidelines for the diagnosis, and prevention
of PE and DVT, the indication for permanent IVC ﬁlter is rated as
Class II a [14,17]. The IVC ﬁlters are recommended for patients con-
traindicated for anticoagulants as Class I in the Japanese guideline
of 2009 [14]. However, the guideline also recommends temporary
IVC ﬁlter for the same group of patients as the permanent IVC ﬁlter,
regardless of the presence of contraindication for anticoagulation.
Thrombus of intra-pelvic vein (including iliac vein) and IVC are
recommended as Class II a for IVC ﬁlter placement. On the other
hand, in the European guideline of 2008, IVC ﬁlter (both temporary
and permanent) may be used when there are absolute contraindi-
cations to anticoagulant and a high risk of VTE recurrence (Class
II b) and the routine use of IVC ﬁlters in patients with PE is not
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ecommended. Our data suggest a high rate of serious compli-
ations following temporary IVC ﬁlter placement, calling for a
arning against wide-spread use of this device. Prospective, ran-
omized trials may  be warranted to accurately assess the risks and
eneﬁts of this technology.
tudy limitations
A retrospective study design with a relatively small sample size
n a single center may  pose a risk for patient selection bias.
eferences
[1] Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, Bengel F,
Brady AJ, Ferreira D, Janssens U, Klepetko W,  Mayer E, Remy-Jardin M,  Bassand
JP,  ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis
and management of acute pulmonary embolism: the Task Force for the Diag-
nosis and Management of Acute Pulmonary Embolism of the European Society
of  Cardiology (ESC). Eur Heart J 2008;29:2276–315.
[2]  Barritt DW,  Jordan SC. Anticoagulant drugs in the treatment of pulmonary
embolism. A controlled trial. Lancet 1960;1:1309–12.
[3] Coon WW,  Willis 3rd PW.  Recurrence of venous thromboembolism. Surgery
1973;73:823–7.
[4] Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW,  Albrechtsson U. Need for long-
term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet
1985;2:515–8.
[5]  Prevention of venous thrombosis and pulmonary embolism. NIH Consensus
Development. JAMA 1986;256:744–9.
[6] Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre
R, Charbonnier B, Barral FG, Huet Y, Simonneau G. A clinical trial of vena caval
ﬁlters in the prevention of pulmonary embolism in patients with proximal
deep-vein thrombosis. Prevention du Risque d’Embolie Pulmonaire par Inter-
ruption Cave Study Group. New Engl J Med  1998;338:409–15.
[7]  Eight-year follow-up of patients with permanent vena cava ﬁlters in the
prevention of pulmonary embolism: the PREPIC (Prevention du Risque
d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation
2005;112:416–22.
[8] Tardy B, Mismetti P, Page Y, Decousus H, Da Costa A, Zeni F, Barral G, Bertrand
JC.  Symptomatic inferior vena cava ﬁlter thrombosis: clinical study of 30 con-
secutive cases. Eur Respir J 1996;9:2012–6.
[9] Ferris EJ, McCowan TC, Carver DK, McFarland DR. Percutaneous inferior
vena caval ﬁlters: follow-up of seven designs in 320 patients. Radiology
1993;188:851–6.
[ology 60 (2012) 306–309 309
10] Greenﬁeld LJ, Proctor MC,  Michaels AJ, Taheri PA. Prophylactic vena caval ﬁlters
in  trauma: the rest of the story. J Vasc Surg 2000;32:490–5.
11] Miyahara T, Miyata T, Shigematsu K, Deguchi J, Kimura H, Ishii S, Nagawa
H. Clinical outcome and complications of temporary inferior vena cava ﬁlter
placement. J Vasc Surg 2006;44:620–4.
12] Millward SF. Temporary and retrievable inferior vena cava ﬁlters: current sta-
tus.  J Vasc Interv Radiol 1998;9:381–7.
13] Lorch H, Welger D, Wagner V, Hillner B, Strecker EP, Herrmann H, Voshage G,
Zur  C, Schwarzbach C, Schroder J, Gullotta U, Pleissner J, Huttner S, Siering U,
Märcklin C, et al. Current practice of temporary vena cava ﬁlter insertion: a
multicenter registry. J Vasc Interv Radiol 2000;11:83–8.
14] Guidelines for the diagnosis, treatment and prevention of pulmonary throm-
boembolism and deep vein thrombosis (JCS 2009). Circ J 2011;75:1258–81.
15] Yamashita T. Frontiers of anticoagulation therapy for atrial ﬁbrillation. J Cardiol
2011;58:1–5.
16] Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H. Investigation of
optimal anticoagulation strategy for stroke prevention in Japanese patients
with atrial ﬁbrillation—the J-RHYTHM Registry study design. J Cardiol 2011;57:
95–9.
17] Ota S, Yamada N, Tsuji A, Ishikura K, Nakamura M,  Isaka N, Ito M.  The Gunther-
Tulip retrievable IVC ﬁlter: clinical experience in 118 consecutive patients. Circ
J  2008;72:287–92.
18] Girard P, Tardy B, Decousus H. Inferior vena cava interruption: how and when?
Annu Rev Med 2000;51:1–15.
19] Kaufman JA, Kinney TB, Streiff MB,  Sing RF, Proctor MC, Becker D, Cipolle M,
Comerota AJ, Millward SF, Rogers FB, Sacks D, Venbrux AC. Guidelines for the
use of retrievable and convertible vena cava ﬁlters: report from the Society of
Interventional Radiology multidisciplinary consensus conference. J Vasc Interv
Radiol 2006;17:449–59.
20] Grassi CJ, Swan TL, Cardella JF, Meranze SG, Oglevie SB, Omary RA, Roberts AC,
Sacks D, Silverstein MI,  Towbin RB, Lewis CA, Society of Interventional Radi-
ology Standards of Practice Committee. Quality improvement guidelines for
percutaneous permanent inferior vena cava ﬁlter placement for the prevention
of  pulmonary embolism. J Vasc Interv Radiol 2003;14(9 Pt 2):S271–5.
21] Kai R, Imamura H, Kumazaki S, Kamiyoshi Y, Koshikawa M,  Hanaoka T, Kogashi
K,  Koyama J, Tsutsui H, Yazaki Y, Kinoshita O, Ikeda U.  Temporary inferior vena
cava ﬁlter for deep vein thrombosis and acute pulmonary thromboembolism:
effectiveness and indication. Heart Vessels 2006;21:221–5.
22] Ohshima K, Hirashiki A, Cheng XW,  Hayashi M,  Hayashi D, Okumura T, Sakak-
ibara M,  Funahashi H, Ohshima S, Murohara T. Impact of mild to moderate
renal dysfunction on left ventricular relaxation function and prognosis in
ambulatory patients with nonischemic dilated cardiomyopathy. Int Heart J
2011;52:366–71.
23] Buller HR, Agnelli G, Hull RD, Hyers TM,  Prins MH,  Raskob GE. Antithrom-
botic therapy for venous thromboembolic disease: the Seventh ACCP
Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3
Suppl.):401S–28S.
